Replies to post #287168 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I’ve long thought it also might be that while waiting for OS in this trial may not justify having used PFS as primary, it very well could justify the correlation in future cancer (Aka: shorten trials) trials with DCVAx-l in different indications with this granddaddy trial providing the Rosetta Stone correlation (if this trial is successful). Of course they can also rely upon many confirming characteristics as well — like immune changes.